Ursin G, Henderson B E, Haile R W, Pike M C, Zhou N, Diep A, Bernstein L
Department of Preventive Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles 90033, USA.
Cancer Res. 1997 Sep 1;57(17):3678-81.
We conducted a study to determine whether the risk of breast cancer associated with oral contraceptive (OC) use is higher in women with BRCA1/BRCA2 mutations than in other women by examining whether breast cancer patients with these mutations were more likely than breast cancer patients without mutations in BRCA1/BRCA2 to have used OCs. We tested for BRCA1 185delAG and 5382insC and BRCA2 6174delT mutations in a population-based sample of 50 young Ashkenazi Jewish breast cancer patients. Nine patients (18%) had a BRCA1 mutation, and five patients (10%) had a BRCA2 mutation. Long-term OC use (>48 months) before a first full-term pregnancy was associated with an elevated risk of being classified as a mutBRCA carrier (odds ratio, 7.8; trend, P = 0.004). The results suggest that OC use may increase the risk of breast cancer more in mutBRCA carriers than in noncarriers; however, they must be interpreted with caution given the small sample size.
我们开展了一项研究，通过检查携带BRCA1/BRCA2突变的乳腺癌患者是否比未携带BRCA1/BRCA2突变的乳腺癌患者更有可能使用口服避孕药（OC），来确定携带BRCA1/BRCA2突变的女性使用OC后患乳腺癌的风险是否高于其他女性。我们在一个基于人群的50名年轻的阿什肯纳兹犹太乳腺癌患者样本中检测了BRCA1 185delAG和5382insC以及BRCA2 6174delT突变。9名患者（18%）携带BRCA1突变，5名患者（10%）携带BRCA2突变。首次足月妊娠前长期使用OC（>48个月）与被归类为携带BRCA突变的风险升高相关（比值比，7.8；趋势，P = 0.004）。结果表明，与非携带者相比，携带BRCA突变者使用OC可能增加更多的患乳腺癌风险；然而，鉴于样本量小，对这些结果的解读必须谨慎。
